Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC

Alex C. Spyropoulos, MD received his medical degree from the University of Pennsylvania School of Medicine in Philadelphia. He completed his internship and residency in internal medicine at the University of New Mexico Health Sciences Center in Albuquerque, NM. He is board certified in Internal Medicine.

Dr. Spyropoulos was Founder and former Medical Director of the Clinical Thrombosis Center in Albuquerque, New Mexico. He is currently a Professor of Medicine at Hofstra, North Shore/LIJ School of Medicine and System Director of Anticoagulation and Clinical Thrombosis Services for the 18-hospital North Shore Long Island Jewish Health System in NY. He is co-chair of the Council on Leadership of Thrombosis at North Shore Long Island Jewish Health System. He is a Fellow of the American College of Physicians, American College of Chest Physicians, International Academy of Clinical and Applied Thrombosis/Haemostasis, and the Royal College of Physicians, Canada.

Dr. Spyropoulos has helped to develop protocols using LMWH in outpatient-based treatment of venous thromboembolic disease, patient self-testing of warfarin, perioperative “bridging” for patients on chronic anticoagulation, medical inpatient thromboprophylaxis, protocols with regards to the use of anticoagulants for HIT, and clinical use of the novel oral anticoagulants, including their use in special patient populations. Dr. Spyropoulos is active in assessing outcome analyses of these protocols and has lectured extensively both nationally and internationally on these issues, He has been involved as Principal Investigator, Scientific Committee member, Steering Committee member, or member of Data Safety Monitoring Board in multiple international, multicenter randomized trials in thrombosis. He is also a Steering Committee member of the NHLBI BRIDGE and Kids DOTT studies and the CIHR PAUSE trial. He is the co-Chair of the Executive Committee for MARINER, a global Phase 3 multicenter study of thromboprophylaxis in medical patients with rivaroxaban, He is a founding member of ATLAS, a US-based AROCRO in thrombosis-related research. He is a panel member of a US national experts consensus group for clinical excellence in thrombosis management, a member of the Anticoagulation Forum and the Thrombosis/Haemostasis Society of North America, co-Chair of the Scientific Standardization Committee of Predictive Variables as part of ISTH, and co-author for the 8th and 9th ACCP Antithrombotic Guidelines, the 2008 International Consensus Statement Guidelines o and is the senior author for the 2013 International Consensus Statement on venous thromboembolic disease. He is also reviewer for the 2014 ESC Guidelines on Pulmonary Embolism. He is Section Editor for Thrombosis and Haemostasis, and is on the editorial staff for Thrombosis Research and Hospital Medicine. He is a reviewer for many journals.

Dr. Spyropoulos’ articles, letters, and editorials have been published in over 140 peer-reviewed journals including Chest, The New England Journal of Medicine, Blood, American Journal of Hematology, American Journal of Medicine, Circulation, Journal of the American College of Cardiology, Clinical Applied Thrombosis Haemostasis, Thrombosis Research, Thrombosis Haemostasis, American Journal of Cardiology, and Journal of Thrombosis and Haemostasis.

University of Pennsylvania College of Arts and Sciences, Philadelphia, PA
Degree: BA, graduated Cum Laude
1985
Field of Study: Biological Basis of Behavior

University of Pennsylvania School of Medicine, Philadelphia, PA
Degree: MD
1992
Field of Study: University Scholar

2001-2002 Honored Member, Strathmore’s Who’s Who 2001-2002 addition